At the 2024 AAAAI Annual Meeting, KalVista and BioCryst presented real-world HAE patient data and oral medication trial results.
At the 2024 AAAAI Annual Meeting, KalVista Pharmaceuticals shared real-world data on HAE patients, highlighting late treatment, anxiety, and barriers affecting prompt on-demand treatment. Meanwhile, BioCryst Pharmaceuticals presented findings on their oral medication, berotralstat, suggesting consistent and significant HAE attack reductions over 18 months, with positive results independent of severity or prior prophylaxis regimen.
February 27, 2024
4 Articles